# Does Zepbound affect birth control?

**Yes, Zepbound may make birth control pills less reliable.** Zepbound (tirzepatide) slows how fast your stomach empties, which can affect how birth control pills are absorbed. The Zepbound label advises switching to a non-oral method, or adding a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. The label says hormonal methods you don't swallow, such as a hormonal IUD, implant, ring, patch or shot, should not be affected; ask your prescriber which option fits you.

*Educational, not medical advice — talk to your prescriber.*

## Why does Zepbound carry a warning about birth control pills?

**Zepbound slows stomach emptying, and in the label's study a pill's hormones were absorbed later and reached a lower peak** [1]. The label describes the delay as "largest after the first dose" and says it "diminishes over time" [1]. That's why the warning is tied to starting and to dose increases, not to every week you take it.

Lilly measured the effect directly. Study participants took a combined pill (0.035 mg ethinyl estradiol with 0.25 mg norgestimate) alongside a single 5 mg dose of tirzepatide. Peak levels of ethinyl estradiol, norgestimate and its active form, norelgestromin, fell by 59%, 66% and 55%. Total hormone exposure fell by 20%, 21% and 23%, and the peak came 2.5 to 4.5 hours later [1].

A lower peak doesn't prove a pill stops working. A 2026 review of this study points out that peak levels fell much more than total exposure, and that "a fall in peak concentration cannot be equated with reduced efficacy" [9]. The label's study measured hormone levels, not pregnancy rates [1]. The label takes the cautious route: it says Zepbound "may reduce the efficacy of oral hormonal contraceptives" and asks for backup during the riskiest weeks [1].

## What does the Zepbound label tell you to do?

**The label gives two options: switch to a non-oral method, or keep your pill and add a barrier method for 4 weeks after starting and 4 weeks after each dose increase.** In the label's words: "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation" [1].

A barrier method means condoms (external or internal), a diaphragm or a cervical cap. If you keep your pill and add a barrier method, keep taking the pill on schedule during the backup weeks. The backup is in addition to the pill, not instead of it.

The warning covers the minipill too. The label's wording is "oral hormonal contraceptives", which includes progestin-only pills as well as combined pills [1]. The study behind the warning used a combined pill, so there are no measurements for progestin-only pills, but the label makes no exception for them.

The Mounjaro label gives the same backup advice [2]. Mounjaro and Zepbound are the same drug, tirzepatide, approved for different conditions.

## How long do you need backup if your dose keeps going up?

**Backup can last months, not 4 weeks, because each dose increase starts a new 4-week window.** The Zepbound label starts at 2.5 mg once weekly for 4 weeks and allows 2.5 mg increases after at least 4 weeks on the current dose, up to 15 mg [1]. Your prescriber sets your dose and decides whether and when to increase it.

Here's how the windows add up if a prescriber increases the dose five times, each at the earliest point the label allows. This is an illustration of the label's backup rule, not a dosing plan.

| Weeks | Step in this example | Backup needed? |
|---|---|---|
| 1–4 | Start | Yes, first 4 weeks after starting |
| 5–8 | Increase 1 | Yes, 4 weeks after an increase |
| 9–12 | Increase 2 | Yes, 4 weeks after an increase |
| 13–16 | Increase 3 | Yes, 4 weeks after an increase |
| 17–20 | Increase 4 | Yes, 4 weeks after an increase |
| 21–24 | Increase 5 | Yes, 4 weeks after an increase |
| 25 onward | No further change | No, per the label |

*Illustrative. Source: Zepbound label, sections 2.1 and 8.3 [1].*

The rule in one line: backup ends 4 weeks after your last dose increase. In the example above, a woman on the pill would use backup for 24 weeks in a row. If her dose went up once and then stayed the same, her backup would end at week 8. Writing down the date of every dose change is the simplest way to know where you are.

To keep track:

1. Write down the date of your first Zepbound dose.
2. Add 4 weeks. If you're keeping your pill, use a barrier method as well until that date. If you're switching methods, ask your prescriber how to stay protected during the switch.
3. Each time your prescriber increases your dose, write down the date of the first higher dose. Backup runs for 4 weeks from that date.
4. If you chose barrier backup, keep taking your pill on schedule the whole time.
5. If you vomit or have diarrhea, check your pill's instructions or ask your pharmacist straight away.

You can also count the dates with the [birth control backup tool](/tools/birth-control-backup).

> **Track it in Linley.** Log the day you start and every dose change. The app counts 4 weeks from each one and reminds you when each 4-week backup window ends.

## Does Zepbound affect an IUD, implant, ring, patch or shot?

**The label says "hormonal contraceptives that are not administered orally should not be affected"** [1]. Methods that don't go through your stomach don't depend on stomach emptying.

| Method | Affected by Zepbound? | Why |
|---|---|---|
| Combined pill | May be; backup advised during the label's windows [1] | Absorbed through the gut |
| Progestin-only pill (minipill) | May be; backup advised during the label's windows | Also an oral hormonal contraceptive [1] |
| Hormonal IUD | Should not be, per the label [1] | Releases hormone in the uterus |
| Copper IUD | No | Contains no hormones |
| Implant | Should not be, per the label [1] | Releases hormone under the skin |
| Vaginal ring | Should not be, per the label [1] | Absorbed through the vaginal wall |
| Patch | Should not be, per the label [1] | Absorbed through the skin |
| Shot (injection) | Should not be, per the label [1] | Injected into muscle or under the skin |
| Condoms, diaphragm | No | Barrier, no hormones |

Some women ask their prescriber to switch them to a ring, patch, implant or IUD when they start Zepbound, so they don't have to track backup windows at all. That is the label's first option [1].

## Do Ozempic and Wegovy affect birth control the same way?

**No. Semaglutide (Ozempic, Wegovy) did not lower birth control pill levels in testing, and its labels carry no backup-contraception advice.** In a 2015 study, 43 postmenopausal women with type 2 diabetes took a combined pill (ethinyl estradiol with levonorgestrel) before and during semaglutide 1 mg. Ethinyl estradiol exposure met the study's bioequivalence criteria, and levonorgestrel exposure was 20% higher on semaglutide, not lower [3].

That study measured pill levels after 13 weeks on semaglutide, not after a first dose, so it isn't a direct comparison with the tirzepatide study. The labels differ, and the label is what your prescriber follows.

The Ozempic label says semaglutide "did not affect the absorption of orally administered medications to any clinically relevant degree" [4]. The Wegovy label says that in trials with "semaglutide 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered medications" [5].

Semaglutide labels do have one pregnancy instruction that Zepbound's doesn't: stop at least 2 months before a planned pregnancy, because semaglutide takes a long time to clear [4][5].

## What if vomiting or diarrhea hits while you're on the pill?

**Vomiting or severe diarrhea can also undercut a pill, separately from the stomach-emptying effect.** Nausea, vomiting and diarrhea are among the most common Zepbound side effects, and the label says most of them happened during dose escalation [1]. CDC's contraception guidance has specific steps for vomiting or diarrhea on combined pills and on progestin-only pills [6].

If you vomit or have diarrhea, check your pill's instructions straight away or ask your pharmacist. What to do depends on the pill and on how soon after taking it you were sick [6]. Tell your prescriber about vomiting or diarrhea that won't stop, since the Zepbound label also links it to dehydration and kidney problems [1].

## Why do people talk about "Zepbound babies"?

**The phrase comes from women who got pregnant unexpectedly while taking a GLP-1 medicine.** We think two things get mixed together: pills that were less reliable during backup windows, and fertility that changes as weight comes down. A 2026 review in *Endocrinology and Metabolism Clinics* notes that GLP-1 medicines improve insulin resistance and androgen levels in women with PCOS (which the review calls PMOS) and "may improve menstrual regularity" [7].

What the label and the evidence support is narrower: oral hormonal contraceptives may be less reliable during the label's backup windows [1], and periods that become more regular can surprise women who assumed they couldn't conceive [7].

## Do you still need birth control in perimenopause?

**Yes, until menopause is confirmed.** Fertility falls in perimenopause, but it doesn't stop. A 2025 article in *Menopause*, the journal of The Menopause Society, says unintended pregnancies still happen in perimenopause, carry a high risk of complications, and that "contraception should continue until menopause is confirmed" [8]. Menopause is confirmed after 12 months without a period [8].

Hormonal birth control can cause or hide bleeding, so if you use it, counting 12 months without a period won't work on its own. Ask your prescriber how you'll know when you can stop contraception.

This matters for women over 40 who start Zepbound while on the pill. Irregular periods in perimenopause can make a missed period easy to dismiss. If you're unsure whether you still need contraception, ask your prescriber before relying on your age.

Some women use a combined pill in perimenopause to manage bleeding or symptoms. Those pills are oral hormonal contraceptives, so the Zepbound backup windows apply to them too [1].

## What if you get pregnant while taking Zepbound?

**Stop Zepbound and tell your prescriber.** The label says "weight loss offers no benefit to a pregnant patient and may cause fetal harm" and advises stopping Zepbound "when a pregnancy is recognized" [1]. Human data are too limited to judge the risk of birth defects or miscarriage. In rats and rabbits, tirzepatide reduced fetal growth, and in rats it caused malformations, at doses that also lowered the mothers' weight and food intake [1].

A 2026 meta-analysis of pregnancies exposed to GLP-1 or GLP-1/GIP medicines around conception or early pregnancy found no clear increase in major birth defects. The authors rated the certainty of that finding "very low", noted that data on individual medicines were sparse, and said the data "preclude conclusions of safety" [10]. The review found no comparative pregnancy outcomes specific to tirzepatide that it could analyze [10].

Lilly runs a pregnancy exposure registry for Zepbound. The label lists it at 1-844-524-0039 [1]. Joining helps build the data that's missing today.

If you're planning a pregnancy, the Zepbound label doesn't set a stop-before-conceiving window the way the semaglutide labels do [1][4]. Tirzepatide's half-life is about 5 to 6 days [1]. Ask your prescriber when to stop.

## Who should be careful, and what to tell your prescriber

**Boxed warning.** "In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND" [1].

**Don't use Zepbound** if you or a family member has had MTC, if you have MEN 2, or if you've had a serious allergic reaction to tirzepatide or any of its ingredients [1].

**Pregnancy.** The Zepbound label says weight loss offers no benefit during pregnancy and may cause fetal harm, and to stop Zepbound when a pregnancy is recognized [1]. Tell your prescriber if you become pregnant while using it [1]. The Mounjaro label, written for type 2 diabetes, says to use Mounjaro in pregnancy only if the potential benefit justifies the potential risk to the fetus [2].

**Breastfeeding.** In a single-dose study of 11 breastfeeding women, tirzepatide was undetectable in 164 of 171 milk samples, and there are no data on effects in breastfed infants or on milk production [1]. Talk to your prescriber about the best way to feed your baby [1].

**Tell your prescriber** about every oral medicine you take. Zepbound slows stomach emptying, which can affect how other pills are absorbed, and the label advises monitoring medicines where small changes in blood level matter, such as warfarin [1]. Birth control pills need the backup this article describes [1]. If you use insulin or a sulfonylurea, your risk of low blood sugar is higher [1]. Tell your care team you take Zepbound before any surgery or procedure with anesthesia or deep sedation, because food or liquid could get into your lungs [1]. Don't combine Zepbound with another product that contains tirzepatide or with any GLP-1 medicine; the label doesn't recommend it [1]. Tell your prescriber if you have severe gastroparesis (very slow stomach emptying); the label doesn't recommend Zepbound for it [1].

**Stop Zepbound and call your prescriber right away** if you have severe stomach pain that won't go away, with or without nausea or vomiting [1]. **Stop Zepbound and get medical help right away** for signs of a serious allergic reaction, such as swelling of the face, lips, tongue or throat, or problems breathing or swallowing [1]. **Tell your prescriber right away** if you have nausea, vomiting or diarrhea that won't go away, or pain in your upper stomach, fever, yellow skin or eyes, or clay-colored stools [1]. **Tell your prescriber** if you have stomach problems that are severe or won't go away, or if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath, or, if you have type 2 diabetes, changes in vision [1]. We suggest also calling if you miss a period or think you could be pregnant.

## FAQ

### If I take a break from Zepbound and restart, do I need backup again?

The label doesn't say. It covers starting and dose increases, not restarting after a pause [1]. Because the slowdown in stomach emptying is largest after a first dose, ask your prescriber whether a restart counts as a new start.

### Does Zepbound affect oral progesterone I take for HRT?

It hasn't been tested. A 2026 review in *Maturitas* searched the research through February 2026 and found no study of tirzepatide with the oral progestogens used in menopausal hormone therapy [9]. The authors call an effect biologically plausible but unproven. Tell the prescriber who manages your HRT that you take Zepbound, especially when you start or change doses.

### Is the advice the same for Zepbound vials and pens?

Yes. Vials and pens contain the same drug and share one label, so the 4-week backup advice applies to both [1].

### Does compounded tirzepatide affect birth control too?

Compounded tirzepatide is not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are sold [11]. It has no FDA-approved prescribing information. The warning exists because tirzepatide slows stomach emptying [1]. That doesn't depend on who made it. Ask your prescriber to apply the same backup rule.

## Sources

1. Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information, boxed warning and sections 1, 2.1, 2.2, 4, 5, 6.1, 7.1, 7.2, 8.1–8.3, 12.2, 12.3, and Medication Guide. Revised 08/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (checked 2026-11-18)
2. Eli Lilly and Company. Mounjaro (tirzepatide) injection, prescribing information, sections 1, 7.2, 8.1 and 8.3. Revised 08/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 (checked 2026-11-18)
3. Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. *J Clin Pharmacol.* 2015;55(5):497–504. PMID 25475122. https://pubmed.ncbi.nlm.nih.gov/25475122/ (checked 2026-11-18)
4. Novo Nordisk. Ozempic (semaglutide) injection, prescribing information, sections 7.2, 8.3 and 12.3. Revised 05/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 (checked 2026-11-18)
5. Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information, sections 7.2, 8.3 and 12.3. Revised 06/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (checked 2026-11-18)
6. Curtis KM, Nguyen AT, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. *MMWR Recomm Rep.* 2024;73(3). PMID 39106301. https://pubmed.ncbi.nlm.nih.gov/39106301/ (checked 2026-11-18)
7. Porterfield F, Mulligan J, Salim K, et al. GLP-1 receptor agonists and reproductive health: implications for contraception, fertility, and pregnancy. *Endocrinol Metab Clin North Am.* 2026;55(4):637–648. PMID 42907053. https://pubmed.ncbi.nlm.nih.gov/42907053/ (checked 2026-11-18)
8. Soltes BA. Contraception in perimenopause. *Menopause.* 2025;32(5):472–474. PMID 40277951. https://pubmed.ncbi.nlm.nih.gov/40277951/ (checked 2026-11-18)
9. Viana DPDC, Invitti AL, Jacobsen L, et al. Tirzepatide and oral progestogens: a hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy. *Maturitas.* 2026;214:109116. PMID 42721915. https://pubmed.ncbi.nlm.nih.gov/42721915/ (checked 2026-11-18)
10. Mavigök E, Mavigök AN. Pregnancy and perinatal outcomes following exposure to GLP-1 and dual GLP-1/GIP receptor agonists: a time-window-stratified systematic review and meta-analysis. *Front Pharmacol.* 2026;17:1994366. PMID 42964193. https://pubmed.ncbi.nlm.nih.gov/42964193/ (checked 2026-11-18)
11. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (checked 2026-11-18)

## Review history

- 2026-11-18: First published. Checked against the Zepbound and Mounjaro labels (revised 08/2026), the Ozempic label (revised 05/2026), the Wegovy label (revised 06/2026), and the sources listed.
